: AbbVie to buy Cerevel Therapeutics in $8.7 billion all-cash deal

AbbVie Inc. said late Wednesday it has agreed to buy Cerevel Therapeutics Holdings Inc. for $8.7 billion, saying that Cerevel’s “robust” neuroscience pipeline adds medications that may transform standards of care in psychiatric and neurological illnesses.

Previous post Earnings Results: C3.ai’s stock drops as AI software company misses on top line
Next post : Nikola’s stock drops 16% after EV company announces equity raise, convertible debt raise